Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) total routine transaction for the first nine months of the year reached 132.7 million yuan, according to a Shanghai bourse disclosure on Saturday.
The pharmaceutical company's Hong Kong shares rose over 1% during Monday's afternoon trade.
The transactions include sales, provision and acceptance of services from related parties, leasing services and donations through related parties.
The estimated cap for the current year is 342.4 million yuan, while that for 2026 is 366.5 million yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments